Non-invasive treatment of prostate cancer with robotic High-Intensity Focused Ultrasound (HIFU) system receives approval for use in European Union.
The system superimposes and blends 3D MR imaging data with that captured using ultrasound. The tumor is then targeted using ultrasound and enables real-time guidance of the energy beam during therapy. This is attributed to the combination of MRI and live ultrasound.
Some of the key characteristics of this system as provided by the company's product description include:
MRI Import and Fusion with real-time ultrasound imaging
Precise contour definition of target areas
Non-invasive ultimate HIFU technology
Precise robotic movements
Unique Dynamic Focusing technology
Real-time tracking and adjustment of energy delivered
Confirmation and possible completion of untreated area